Quality of Life of Patients with Ovarian Cancer by Wei-Chu Chie & Elfriede Greimel
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
17 
Quality of Life of Patients with Ovarian Cancer 
Wei-Chu Chie1 and Elfriede Greimel2 
1Institute of Epidemiology and Preventive Medicine,  
College of Public Health, National Taiwan University  
2Department of Obstetrics and Gynaecology, Medical University Graz, Graz  
1Taiwan 
2Austria 
1. Introduction 
1.1 Current status of ovarian cancer 
Ovarian cancer is one of the leading female cancers around the world (International Agency 
for Research on Cancer, 2011). Up to now, there is no effective method of early detection (US 
Task Force of Preventive Services, 2011). When detected, the stages are usually advanced, 
and patients have poor prognosis and poor health-related quality of life (HRQoL). Patient-
reported outcomes have been recommended as endpoints of clinical trials by the U.S. Food 
and Drug Administration (FDA) (2011). Therefore, besides improving survival, a better 
HRQoL is a major goal for the development of methods for new detection and treatments. 
1.2 The impacts of the disease 
Patients with ovarian cancer share general functioning and systemic problems with patients 
with other cancers (Cella et al., 1993; Cain et al., 1998; Base-Enquist et al., 2001; Aaronson et al., 
1993). Regarding disease-specific problems, abdominal / gastrointestinal symptoms because of 
the space-occupying nature of the tumor and the malignant ascites from the tumor in the 
pelvic and abdominal cavity are most important issues (Cain et al., 1998; Base-Enquist et al., 
2001; Cull et al., 2001; Greimel et al., 2003a, 2003b). The disease recurs easily. Patients may 
suffer repeating debulking surgeries and chemotherapies that affect their HRQoL. 
1.3 The impacts of the treatments 
The standard treatment of this disease is debulking (cytoreduction) surgery followed by 
platinum-based chemotherapy (du Bois at al., 2005), while a new approach of neoadjuvant 
chemotherapy followed by debulking surgery (Brisow & Chi, 2006). These treatments, no 
matter which comes first, can improve survival and improve HRQoL of patients by 
reducing tumor size and ascites, and also patients’ psychological distress. But they may also 
have negative impacts on HRQoL of patients because of the adverse effects of chemotherapy 
and surgery. 
1.4 Other important aspects of HRQoL 
The life-threatening nature of the illness can also cause psychological distress (Cull et al., 
2001; Greimel et al., 2003a, 2003b). As all other gynecological cancers, patients with ovarian 
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cancer suffer from body image concerns and problems in sexual life (Cain et al., 1998; Base-
Enquist et al., 2001; Cull et al., 2001; Greimel et al., 2003a, 2003b). 
2. Domains of HRQoL affected by disease and treatments of ovarian cancer 
2.1 Disease-related problems 
2.1.1 General functioning and systemic symptoms 
General functioning including physical, emotional, social, etc. (Cella et al., 1993; Aaronson et 
al., 1993) and ability of getting around (independence) are major issues in this category 
(Cain et al., 1998; Base-Enquist et al., 2001). Weight loss is also seen as a disease-related 
systemic symptom for advanced tumor (Cain et al., 1998; Base-Enquist et al., 2001). 
2.1.2 Abdominal (gastrointestinal) symptoms 
Abdominal (gastrointestinal) symptoms are major disease-related HRQoL problems of 
patients with ovarian cancer. These symptoms may include abdominal swelling, fullness, 
pain or cramps, indigestion, change of bowel habit, etc. Abdominal pain and bowel habit 
change can also arise from treatment (Cain et al., 1998; Base-Enquist et al., 2001; Cull et al., 
2001; Greimel et al., 2003a, 2003b). 
2.2. Treatment-related problems 
2.2.1 Urological and gynecological symptoms 
The urological or gynecological symptoms are not as common as other gynecological 
cancers, and they are usually caused by treatment. Urinary frequency and dry vagina are 
often complained of (Cull et al., 2001; Greimel et al., 2003a, 2003b). 
2.2.2 Chemotherapy side effects 
Chemotherapy can cause nausea and vomiting, poor appetite (Cella et al., 1993; Cain et al., 
1998; Base-Enquist et al., 2001; Aaronson et al., 1993), hair loss (Cain et al., 1998; Base-
Enquist et al., 2001; Cull et al., 2001; Greimel et al., 2003a, 2003b), peripheral neuropathy 
including numbness and weakness, other sensory change, skin problems and muscle pain 
(Cull et al., 2001; Greimel et al., 2003a, 2003b). Urinary frequency can also be attributed to 
chemotherapy (Cull et al., 2001; Greimel et al., 2003a, 2003b). 
2.2.3 Termination of reproductive ability and menopausal symptoms 
For women of reproductive age, both surgical treatment and chemotherapy can cause early 
menopause and the termination of reproductive ability (Cain et al., 1998; Base-Enquist et al., 
2001). Menopausal symptoms caused by hormonal depletion, including hot flush (flash) and 
night sweats, are also experienced by these patients (Cull et al., 2001; Greimel et al., 2003a, 
2003b). 
2.3 Other important aspects in HRQoL 
2.3.1 Body image and psychological problems 
Like all other gynecological cancer, ovarian cancer per se and its treatment can cause body 
image and psychological problems. For the body image problems, patients may feel less 
attractive, less like a woman, dissatisfied with body or appearance, etc. (Cain et al., 1998; 
Base-Enquist et al., 2001; Cull et al., 2001; Greimel et al., 2003a, 2003b). For the psychological 
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problem, patients may have negative emotions (Cella et al., 1993; Aaronson et al., 1993), or 
suffer from burdens of and worries about disease or treatment (Cull et al., 2001; Greimel et 
al., 2003a, 2003b). 
2.3.2 Sexuality 
Like all other gynecological cancers, sexuality is negatively affected. Issues include interest 
in sex, real sexual activity and enjoyment (Cain et al., 1998; Base-Enquist et al., 2001; Cull et 
al., 2001; Greimel et al., 2003a, 2003b). Dry vagina during intercourse, a result of hormonal 
depletion, can also be classified in this category (Cull et al., 2001; Greimel et al., 2003a, 
2003b). 
3. Existing instruments for assessment of HRQoL 
We have at present two systems of disease-specific instruments for assessment of HRQoL of 
patients with ovarian cancer: the Functional Assessment of Cancer Therapy (FACT) and the 
European Organisation for Research and Treatment of Cancer (EORTC). Both have a generic 
core questionnaire, the FACT-G and the EORTC QLQ-C30, and a disease-specific 
supplementary questionnaire, the FACT-O and the EORTC QLQ-OV28.  
3.1 The FACT system: FACT-G and FACT-O 
3.1.1 The scale structure of the FACT system 
The FACT-G was developed as a general measure for HRQoL of patients with cancer in 1987 
(Cella et al., 1993) and validated in patients with different cancers before the development of 
ovarian specific scale (Weitzner et al., 1995; Cella, 1995; List at al., 1996; Brady at al., 1997; 
Esper at al., 1997; Yellen at al., 1997; McQuellon et al., 1997; Ward at al., 1999). The 
instrument contains four domains and 27 questions: physical well-being (PWB), 7 questions; 
social / family well-being (SWB), 7 questions; emotional well-being (EWB), 6 questions; and 
functional well-being (FWB), 7 questions (Cella et al., 1993). Each question has 5 options: 0 
(not at all), 1 (a little bit), 3 (quite a bit), and 4 (very much). All item scores are recoded to 
make a high score corresponding to better HRQoL. It can be seen either as a disease-specific 
instrument vs. other diseases or a generic instrument for all patients with cancer. An ovarian 
cancer-specific subscale (OCS) was developed in 1998 using the same option format (Cain et 
al., 1998) and was reported to have good reliability and validity in 2001 (Base-Enquist et al., 
2001). The questionnaire contains one domain, originally 12 questions: stomach swelling, 
losing weight, vomiting, hair loss, stomach cramping, and concerns about fertility (negative 
questions); bowel control, good appetite, appearance, getting around, feel like a woman, and 
interested in sex (positive questions, reverse coded). One question (concerns about fertility) 
was deleted because most patients are beyond childbearing age. The two instruments are 
used together when assessing HRQoL of patients with ovarian cancer. The score of each 
scale is a summation of recoded question scores within each scale. The total score is a 
summation of all scores of all 38 (27 and 11) questions together. 
3.1.2 Reliability and validity of the FACT system in patients with ovarian cancer 
Reliability and validity of the FACT-O with FACT-G were reported by Base-Enquist et al. 
(2001). The internal consistency (Cronbach’s alpha) coefficient of the 11 questions in FACT-
O was 0.92, and test-retest correlation coefficient of the total FACT-O score was 0.81. The 
correlation coefficients between the total FACT-O score, subscale scores of FACT-G, and 
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subscale scores of other related instruments were as expected (good convergent and 
divergent validity). The scores of subscales of the FACT-G and the total FACT-O score were 
significantly different in different performance and treatment status, and were sensitive to 
changes of performance status. According to the validation results, the FACT-O is a reliable 
and valid instrument used with the FACT-G in assessment of ovarian cancer-specific 
HRQoL as a whole for patients with ovarian cancer. 
3.2 The EORTC system: QLQ-C30 and QLQ-OV28 
3.2.1 The scale structure of the EORTC system 
The development of the EORTC QLQ-C30 can be traced back in 1986. The questionnaire was 
designed for the measurement of general HRQoL issued for patients with cancer (Aaronson 
et al., 1993). It can also be seen either as a disease-specific instrument vs. other diseases or a 
generic instrument for all patients with cancer. The questionnaire contains 30 questions 
belonging to five functional scales (physical, role, emotional, social, and cognitive), nine 
symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite 
loss, constipation, and diarrhea), financial difficulty in the past week, and one global health 
status (overall health and quality of life) scale. Each question has 4 options: 1 (not at all), 2 (a 
little), 3 (quite a bit), and 4 (very much). Each scale is scored separately. There is no total 
score. All scale scores are transformed into 0-100 from a recoded summation of item scores 
in each scale. For all functional scales, a higher score represents a better HRQoL. For all 
symptom scales and financial difficulty, a higher score means a poorer HRQoL. Previous 
studies showed good reliability and validity for different cancer diagnoses (Bjordal & Kaasa, 
1992; Aaronson et al., 1993; Hjermstad et al., 1995; Groenvold et al., 1997; Kobayashi et al., 
1998). 
The EORTC QLQ-OV28 was designed as a supplement to the EORTC QLQ-C30 for the use 
in ovarian cancer clinical trials and related studies (Cull et al., 2001; Greimel et al., 2003a, 
2003b). It contains seven subscales and 28 questions – abdominal / gastrointestinal 
symptoms (7 questions: abdominal pain, feeling bloated, clothes too tight, changed bowel 
habit, flatulence, fullness when eating, indigestion), peripheral neuropathy (4 questions: 
tingling, numbness, and weakness), other chemotherapy side-effects (7 questions: hair loss 
and upset by hair loss, taste change, muscle pain, hearing problem, urinary frequency, and 
skin problem), hormonal / menopausal (2 questions: hot flushes and night sweat), body 
image (2 questions: less attractive, dissatisfied with body), attitude to disease and treatment 
(3 questions: disease burden, treatment burden, and worry about future), and sexual 
function (4 questions: interest in sex, sexual activity, enjoyment of sex, and dry vagina). Each 
scale is scored separately as that of the EORTC QLQ-C30. For symptom scales, a higher 
score means a poorer HRQoL. For function scales (body image and sexual function), a 
higher score represent a better HRQoL. In addition to the cross-cultural validation of the 
EORTC, Chie et al. (2010) reported the translation and validation of the EORTC QLQ-OV28 
in Taiwan and found a relatively low importance of body image, menopausal, and sexuality 
problems because of low emphasis on attractiveness and avoidance of sexual activity after 
having cancer. 
3.2.2 Reliability and validity of the EORTC system in patients with ovarian cancer 
Greimel et al. (2003b) reported the result of cross-cultural validation of the EORTC QLQ-
OV28 used with the EORTC QLQ-C30. The internal consistency (Cronbach’s alpha) 
coefficients of all subscales except body image (0.58) were above 0.70 (ranging from 0.77 to 
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0.90). There was no scaling error except the subscale of other chemotherapy side effects 
(5/42). The intraclass correlation coefficients for test-retest of all subscales ranged from 0.74 
to 0.94. The correlation coefficients between subscales of the EORTC QLQ-OV28 and EORTC 
QLQ-C30 were as expected. For responsiveness, scores of abdominal symptoms, peripheral 
neuropathy, other chemotherapy side effects, and disease burden responded significantly 
after treatment. For sensitivity (known-groups comparison), subscale scores differed most 
significantly between patients with primary and recurrent tumors. According to the 
validation report, the EORTC QLQ-OV28 is a reliable and valid multi-dimensional 
instrument used with the EORTC QLQ-C30 for the assessment of HRQoL of multiple 
aspects for patients with ovarian cancer. 
3.3 Comparison of scale structures of the two systems 
The comparison of the two sets of instruments is shown in Tables 1 and 2. The functional 
scales of the FACT-G and the EORTC QLQ-C30 are similar. Both include physical, mental 
or emotional, social, and role or functional subscales. The FACT-G emphasizes familial 
functioning, while the EORTC QLQ-C30 includes cognitive functioning. Both have an 
overall measure for HRQoL: the FACT-G uses a summation of all scores, while the 
EORTC QLQ-C30 measures it separately. The EORTC QLQ-C30 also has symptom and 
financial difficulty subscales. The FACT-G includes some symptoms in physical or 
function subscales (Table 1). The contents of the FACT-O and the EORTC QLQ-OV28 are 
similar. However, the FACT-O has only one overall scale for ovarian cancer, while the 
EORTC QLQ-OV28 has seven subscales covering problems of different organ-systems or 
aspects of HRQoL (Table 2). 
 
FACT EORTC 
Physical  Energy Physical  Strenuous activity 
 Nausea   Long walk 
 Family needs   Short walk 
 Pain   Stay in chair 
 Side effects  Self-care 
 Feel ill   
 Bed-ridden   
Social /family Close to friends Social  Interfere with family life 
 Family support  With social activities  
 Friends’ support   
 Family comm. illness   
 Close to partner   
 Sexual life   
Emotional  Feel sad Emotional  Tense 
 Satisfied with coping  Worry  
 Losing hope  Irritable  
 Feel nervous  Depressed  
 Worry / dying Cognitive  Concentration  
 Worry / getting worse  Remembering  
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FACT EORTC 
Functional  Able to work Role  Limited work 
 Work fulfilling  Limited leisure 
 Enjoy life   
 Sleep well    
 Enjoy pleasure   
 Content with QOL Overall  Health  
   QOL 
Symptoms   Pain, Fatigue, Nausea & vomiting 
Dyspnea, Sleep, Appetite, constipation, 
diarrhea  
Other scale(s)  Financial difficulty 
Table 1. Comparison of FACT-G and the EORTC QLQ-C30. 
 
FACT EORTC 
FACT-O (one scale) 
Stomach swelling, losing weight, bowel 
control, vomiting, hair loss, good appetite, 
appearance, getting around, feel like a 
woman, stomach cramping, interested in sex, 
concerns about fertility (deleted) 
GI symptoms Abdominal pain, 
Feeling bloated, 
Clothes tight, 
Changed bowel 
habit, Flatulence, 
Fullness when 
eating, Indigestion  
Peripheral 
neuropathy 
Tingling, 
Numbness, 
Weakness 
Other 
chemotherapy 
side effects 
Hair loss & upset, 
Taste change, 
Muscle pain, 
Hearing problem, 
Urinary frequency, 
Skin problem 
Attitude to 
disease 
Disease burden, 
Treatment burden,  
Worry about future 
Sexual function Interest in sex, 
Sexual activity, Sex 
enjoyment,  Dry 
vagina 
Table 2. Comparison of FACT-O and the EORTC QLQ-OV28. 
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4. Equivalence of the FACT and the EORTC systems 
Are the results of the two systems equivalent? Hozner et al. (2006) reported a study on 737 
patients with different cancers for the equivalence of the FACT-G and the EORTC QLQ-C30, 
the core content of the two systems. Both classical test theory and Rasch measurement 
model were used. Three of the four subscales common to the two systems are equating: 
physical, emotional, and role / functional, but not the social / family subscale. A converting 
table was generated according to the results. No such study was conducted for the FACT-O 
and the EORTC QLQ-OV28 because the FACT-O has only one subscale, therefore the two 
site-specific questionnaires have no common subscales to study. 
5. Application of two systems in assessing HRQoL of patients with ovarian 
cancer undergoing different treatments across different cultures 
5.1 The application of the FACT system 
The two systems of instruments measuring HRQoL of patients with ovarian cancer were 
used in clinical trials and non-trial clinical studies. The FACT system was more widely used 
because the FACT-O was developed earlier than the EORTC QLQ-OV28. The FACT-O has 
been applied in studies assessing palliative chemotherapy for advanced ovarian cancer 
(using EORTC QLQ-C30 and FACT-O) (Doyle et al., 2001), general chemotherapy ( Le et al., 
2004), adjuvant and salvage chemotherapy for advanced ovarian cancer (Le et al., 2005), 
interval cytoreduction in advanced ovarian cancer (Wenzel et al., 2005), active coping 
(Canada et al., 2006), Thallidomide therapy (Gordinier et al., 2007), phase I/II gemcitabine 
and doxirubicine (Goff et al., 2003)] and phase II gemicitabine and topotecan trials for 
platinum-refractory ovarian cancers (Goff et al., 2008), and factors for decreased QoL (von 
Gruenigen et al., 2009). In summary, the FACT-O and FACT-G scores became better when 
there was response to treatment, active coping can improve HRQoL, and factors causing 
decreased HRQoL can be detected and managed in advance. 
5.2 The application of the EORTC system 
The use of the EORTC QLQ-OV28 with the EORTC QLQ-C30 was less common because it 
was developed later than the FACT-O. The two questionnaires were first used in a study 
assessing HRQoL for patients after pelvic exenteration in 2004 (Roos et al., 2004) where more 
physical, social, and sexual problems, especially for young patients were reported after 
surgery. A comparison of HRQoL of patients with early vs. advanced ovarian cancer 
(Mirabeau-Beale et al., 2009) found comparable HRQoL in two groups. A clinical trial of 
neoadjuvant platinum-based chemotherapy followed by (interval) debulking surgery vs. 
standard care of primary debulking surgery followed by platinum-based chemotherapy in 
stage IIIC or IV ovarian cancer used the two questionnaires did not detect any difference 
between the two arms in HRQoL (Vergote et al., 2010). The EORTC QLQ-C30 alone without 
the EORTC QLQ-OV28 has been used in a randomized trial of cisplatin / paclitaxel vs. 
carboplatin / paclitaxel and found patients undergoing carboplatin / paclitaxel treatment 
had better HRQoL (Greimel et al., 2006). Another study using the EORTC QLQ-C30 
assessing the HRQoL of long-term survivors of ovarian cancer found long-term survivors 
had better HRQoL scores before treatment than short-term survivors, and long-term 
survivors had significant improvement of HRQoL in emotional and global health scores 1 
year after treatment and remained stable. The scores of all domains but dyspnea were 
comparable with women without cancer (Greimel et al., 2011). 
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5.3 A comparison of the two systems in HRQoL assessment 
A review article in 2010 commented after comparing all generic and specific questionnaires 
for HRQoL of patients with gynecologic cancers that there is little evidence that disease-, 
symptom- or treatment-specific instruments are more responsive or sensitive than generic or 
cancer-specific questionnaires, and a superior quality and quantity data reported for the 
FACT system compared with the EORTC system (Luckett et al., 2010). Nordin and Greimel 
on behalf of the EORTC Quality of Life Gynecology Group (2010) responded in a letter that 
such comments are not substantiated and provided examples of good results of cross-
cultural validation. In addition to the cross-cultural nature, the multi-dimensional structure 
of the EORTC system may also help clinical researchers and practitioners conduct more 
detailed assessment of different aspects of HRQoL of patients. 
6. Future development 
Ovarian cancer is an important gynecological cancer which affects the survival and HRQoL 
of patients (International Agency for Research on Cancer, 2011). The keys to improve both 
survival and HRQoL are methods of early detection (US Task Force of Preventive Services, 
2011) and effective treatment (du Bois at al., 2005; Brisow & Chi, 2006). We expect 
breakthroughs in both early detection and effective treatment in the near future. Patient-
reported outcomes have been recommended as endpoints of clinical trials by the U.S. Food 
and Drug Administration (FDA) (2011). To evaluate the effectiveness of these methods, 
HRQoL is an essential primary endpoint. Two systems of HRQoL assessment, i.e. the FACT 
and the EORTC systems are available. Both cover major issues of HRQoL and show good 
reliability and validity in previous reports and are used widely around the world in clinical 
trials and clinical studies. Therefore, we expect that the assessment of HRQoL of patients 
can be routinely included in clinical researches and practice, to understand and further 
improve patients’ HRQoL. 
7. Conclusions 
Ovarian cancer is one of the leading female cancers around the world. There is no effective 
method of early detection. When detected, the stages are usually advanced, and patients 
have poor health-related quality of life (HRQoL). The standard treatments of this disease 
including debulking surgery and chemotherapy can improve survival and may have either 
positive or negative impacts on HRQoL of patients. The disease recurs easily. Patients may 
suffer repeating debulking surgeries and chemotherapies that affect their HRQoL. In this 
chapter, we introduced and reviewed the scale structures, psychometric properties and 
clinical validities of existing instruments – the FACT system and the EORTC system for the 
assessment of HRQoL for patients with ovarian cancer, and report the results of their 
application in clinical trials and observational studies. We hope that HRQoL can be 
emphasized and routinely assessed for all patients with ovarian cancer in future clinical 
researches and practice. 
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